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Introduction
Cardiogenic shock is a rare complication, but a deadly one 
in patients with acute myocardial infarction. In previous 
registries, which represents real-world practice, the rate of 
cardiogenic shock in populations with acute coronary syn-
dromes (ACS) ranged from 1% to 4.6%.1,2 Despite limited 
evidence from randomized controlled trials, intra-aortic 
balloon pump (IABP) counterpulsation was recommended 
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as class I treatment in patients with infarct-related cardio-
genic shock in previous guidelines of the American Heart 
Association/American College of Cardiology and the 
European Society of Cardiology and is the most commonly 
used mechanical assistance device in that context.3,4
More recently, there was a suggestion from several 
meta-analysis that the use of IABP might not be associated 
with any survival improvement, although not all results 
were identical.5,6 More recently, in the contemporary era of 
myocardial infarction treatment, the IABP-SHOCK II trial 
showed no benefit with the use of IABP in patients with 
cardiogenic shock.7 However, these results do not always 
reflect real-world treatment practice and sometimes the 
translation to real-life populations is not always adequate.
The aim of our study was to assess the role of IABP 
treatment in patients with acute myocardial infarction com-
plicated by cardiogenic shock from a large nationwide reg-
istry of ACS. This registry reflects real-life treatment and 
we intended to study the potential beneficial or harmful 
effects of IABP.
Methods
We included consecutive adult patients (⩾ 18 years) from 
the Portuguese Registry on Acute Coronary Syndromes 
(ProACS) between 1 January 2002 and 31 October 2013. 
This registry is a continuous, prospective and observa-
tional registry, with 33 participating cardiology depart-
ments from Portugal (continental and islands).8,9 Acute 
myocardial infarction (MI) diagnosis was defined accord-
ing to the universal definition criteria for type 1 myocar-
dial infarction.10 Inclusion criteria in the registry were a 
history of chest pain at rest or other symptoms suggestive 
of an ACS (the most recent episode occurring within 48 h 
of admission) with or without new or presumed new sig-
nificant ST-segment–T wave changes/new left bundle 
branch block or elevated levels of biomarkers of myocar-
dial damage with a rise and/or fall of these markers. A per-
sistent (> 30 min) ST-segment elevation was considered 
ST elevation MI (STEMI). All other cases with elevated 
levels of biomarkers of myocardial damage were consid-
ered non-STEMI (NSTEMI).
For the purpose of the present study, only patients admit-
ted in Killip–Kimbal class IV or who developed it in the 
first 24 h after admission with early revascularization 
planned were selected. Cardiogenic shock was defined by a 
systolic blood pressure of less than 90 mmHg for more than 
30 min or if the patient needed infusion of catecholamines 
to maintain a systolic blood pressure above 90 mmHg, had 
clinical signs of pulmonary congestion, and had impaired 
end-organ perfusion.
Data was registered in a dedicated computer database, 
including demographic, clinical and patient management-
related characteristics, as well as clinical outcomes. 
Hypertension, diabetes and hyperlipidaemia were defined 
as either previously known or on specific therapy. If the 
patients had smoked during the previous 30 days they were 
classified as smokers and were self-reported.
Decisions on patient management strategy, including 
referral for coronary angiography and performance/mode 
of myocardial revascularization (either percutaneous coro-
nary intervention (PCI) or coronary artery bypass grafting 
(CABG)) were left to the attending physician and the site-
specific protocols. Significant coronary artery stenosis was 
defined as more than 50% of luminal obstruction.
Our primary end point was all-cause mortality during 
the index hospitalization. We also considered other second-
ary end points: in-hospital re-infarction, mechanical com-
plications, cardiac arrest and the composite end point of 
death/re-infarction. Recurrent chest pain for more than 20 
min with new ECG changes and/or a new increase in bio-
markers of myocardial necrosis (increase > 20% in troponin 
compared with previous levels) were considered a re-
infarction. Six-month all-cause mortality was also assessed.
We also considered some safety end points: stroke/tran-
sient ischaemic attack (TIA) and major bleeding. Stroke/
TIA was defined by the presence of new neurological 
symptoms with associated signs of ischaemia or bleeding 
on computed tomography or magnetic resonance imaging. 
Major bleeding was evaluated according to the Global Use 
of Strategies to Open Occluded Coronary Arteries 
(GUSTO) criteria – intracranial bleeding or significant 
bleeding with haemodynamic compromise requiring spe-
cific intervention.11
The study complies with the 1975 Declaration of 
Helsinki. The ethics committee for clinical research 
approved the study and patients gave their informed con-
sent. This registry is registered at ClinicalTrials.gov with 
the identification number: NCT01642329.
Statistical analysis
Categorical variables are reported as percentages and con-
tinuous variables are reported as mean ± standard deviation. 
Differences between groups for discrete variables were 
tested with the chi-squared test or Fisher’s exact test as 
appropriate. We used the two-tailed Student’s t-test to com-
pare continuous variables. Continuous variables without 
normal distribution are reported as median and inter-quartile 
range and were compared with the Mann–Whitney test.
Multivariable logistic regression models (with forward 
stepwise selection) were used to assess the association of 
IABP therapy with all-cause in-hospital mortality and the 
composite end point death/re-infarction. Variables were 
removed from the model when the p-value exceeded 0.10. 
Factors that remained significant at the 0.05 level in the 
multivariable models were considered to be significant 
contributors and were kept in the model. Potential con-
founding factors offered to the logistic regression models 
included: age, gender, diabetes, hypertension, smoking 
status, hyperlipidaemia, renal failure, prior MI, prior revas-
cularization, prior stroke, STEMI diagnosis, multi-vessel 
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disease. The estimates of the association between predic-
tors and end points are presented as odds ratios (ORs) with 
95% confidence intervals (CIs).
For all-cause in-hospital mortality and the composite 
end point death/re-infarction, specific subgroup analysis 
was performed in subgroups defined according to gender, 
age (< 65 years, 65–74 years, or ⩾ 75 years), presence or 
absence of diabetes, STEMI versus NSTEMI, with or with-
out mechanical complications, and previous or no previous 
MI. The interaction analysis between IABP therapy and 
each subgroup variable was performed considering multi-
variable logistic regression models.
We also performed a propensity score matching analysis 
to further adjust for the non-randomized assignment of 
patients to treatment and for the potential bias due to differ-
ences in both study groups. A propensity score was calcu-
lated for each individual by logistic regression as the 
likelihood of assignment to treatment with an IABP. The 
propensity model consists of the following variables: age; 
gender; hypertension; diabetes; hyperlipidaemia; smoking 
status; previous PCI, CABG, MI, stroke/transient ischae-
mic attack and peripheral arterial disease; ACS type; admis-
sion by the emergency medical system; admission heart 
rate and systolic blood pressure; in-hospital treatment with 
acetyl-salicylic acid, clopidogrel, angiotensin converting 
enzyme (ACE) inhibitor, beta-blocker and statins; left main 
disease; multivessel disease; and in-hospital PCI or CABG. 
Then we performed a 1 to 1 or 1 to 2 (whenever possible) 
matched analysis on the basis of the estimated propensity 
score of each patient. A standardized difference of less than 
5% supports the assumption of balance between the two 
groups. After this propensity score matching, baseline and 
in-hospital characteristics were compared.
Estimates of event-free survival at six-month follow-up 
were calculated by the Kaplan–Meier method and curves 
were compared with the log-rank test. We used a Cox pro-
portional-hazards regression model with the p level for 
entry into and removal from the model set at 0.05 and 0.10, 
respectively (with a forward stepwise with likelihood ratio 
statistic method) for selecting independent predictive vari-
ables for all-cause mortality. The estimates of the associa-
tion between predictors and endpoints are presented as 
hazard ratios (HRs) with 95% CI. This analysis was applied 
in both the baseline study groups as well as in the propen-
sity score matched groups.
For all statistical analysis, we used the IBM SPSS statis-
tics software package (version 19.0.0.2). All statistical tests 
were two-sided with a critical value of 0.05 for statistical 
significance.
Results
From a total of 33,300 patients included in the registry dur-
ing the study period, 1481 (4.2%) developed cardiogenic 
shock on admission or in the first 24 h after admission 
(Figure 1). From these, 646 patients (43.6%) underwent 
coronary angiography in the first 24 h and were selected for 
the present analysis. Excluded patients were older, less fre-
quently males, with fewer risk factors and previous PCI 
(despite a higher rate of previous MI). They also presented 
less frequently with STEMI and had lower heart rate and a 
worse Global Registry of Acute Coronary Events (GRACE) 
risk score (Supplementary Material Table 1 online). They 
received less medication and less primary PCI, with higher 
rates of thrombolysis and mortality. In this population, 22.7% 
died very early (< 24 h after admission) (vs. 15.6% in the 
study population, p<0.001) and 51.0% were initially admit-
ted in a hospital without catheterization facilities (vs. 29.7%, 
p<0.001), which might have been one possible explanation 
for not being submitted to early invasive strategy.
The mean age of our study population was 69 ± 12 years, 
65% males and only 19.8% received IABP therapy. Patients 
in the IABP group were younger (Table 1). They were less 
often referred by the emergency medical system and had 
higher heart rate on admission. On coronary angiography 
they had more often multivessel or left main disease. The 
proportion of patients with STEMI was similar between both 
groups; however, anterior myocardial was more often pre-
sent in patients that received IABP. All other baseline charac-
teristics are well balanced between the two groups (Table 1).
The procedure most often used for revascularization was 
primary PCI in patients with STEMI and also PCI in NSTEMI 
patients. In the index hospitalization, only 2.4% of patients 
underwent CABG and in 16% of the patients no revasculari-
zation procedure was performed. Concomitant medications 
are shown in Table 1 and were also well balanced, with the 
exception of a trend to a lower use of acetyl salicylic acid and 
higher use of statin in the group without IABP.
Primary and secondary end points
In-hospital mortality rate was 40.2%, slightly higher in the 
group that received IABP (OR 1.35, 95% CI 0.91–1.99, 
p=0.132) (Table 2). Also re-infarction was slightly higher 
in the group with IABP (OR 2.11, 95% CI 0.96–4.63, 
Figure 1. Flowchart of patient selection for inclusion in the 
study.
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Table 1. Clinical characteristics by study group.
Without IABP 
n=518
With IABP 
n=128
p-value
Age, years 69 ± 12 65 ± 12 0.001
Male gender, % 65.0 67.2 0.593
BMI, kg/m2 26.6 (24.2–29.1) 26.3 (24.5–28.4) 0.761
Risk factors, %  
 Hypertension 61.9 62.2 0.943
 Hyperlipidaemia 42.9 46.8 0.431
 Diabetes 29.6 33.1 0.453
 Smoking 24.1 31.5 0.086
Previous history, %  
  Myocardial infarction 14.8 10.2 0.177
  PCI 10.1 7.8 0.437
  CABG 2.5 0.8 0.323
  Stroke/TIA 9.1 10.2 0.715
  PAD 6.8 3.1 0.115
Initial presentation  
  EMS, % 22.7 12.5 <0.001
  Heart rate, beats/min 81 ± 28 91 ± 29 0.001
  SBP, mmHg 108 ± 38 103 ± 31 0.145
  Killip class IV, admission, % 47.8 51.2 0.199
  STEMI, % 82.6 80.5 0.429
   Anterior 51.9 71.8 <0.001
   Thrombolysis 12.2 10.2 0.607
   Primary PCI 87.8 89.8 0.618
Laboratory dataa  
  Creatinine, mg/dl 1.2 (0.9–1.6) 1.2 (1.1–1.6) 0.323
  eGFR, ml/min per 1.73m2 55 (37–76) 60 (41–82) 0.692
  Blood glucose, mg/dl 174 (133–260) 219 (156–280) 0.075
GRACE risk score 190 (161–213) 192 (150–218) 0.751
Multivessel disease, % 56.0 63.0 0.014
Left main disease, % 11.6 25.1 <0.001
Treatment, %  
  ASA 94.5 98.4 0.061
  Clopidogrel 83.7 85.9 0.540
  ACEI 53.1 49.6 0.486
  Beta-blocker 41.8 41.3 0.912
  Statin 79.3 72.2 0.087
  PCI 82.5 87.3 0.190
  CABG 2.0 4.0 0.092
aData from only the 223 patients included since 1 October 2010 (second phase of the ProACS registry).
IABP: intra-aortic balloon pump; BMI: body mass index; PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting;  
TIA: transient ischaemic attack; PAD: peripheral arterial disease; SBP: systolic blood pressure; EMS: emergency medical system; STEMI: ST elevation 
myocardial infarction; eGFR: estimated glomerular filtration rate; GRACE: Global Registry of Acute Coronary Events; ASA: acetyl salicylic acid; 
ACEI: angiotensin converting enzyme inhibitor.
Table 2. Outcomes and complications in both study groups.
Without IABP 
n=518
With IABP 
n=128
p-value
All-cause hospital mortality, % 38.8 46.1 0.132
Hospital re-infarction, % 3.9 7.8 0.057
Death/re-infarction 40.3 50.8 0.032
Mechanical ventilation, % 24.5 63.3 <0.001
Mechanical complication, % 9.3 9.4 0.893
Cardiac arrest, % 23.4 28.1 0.260
Stroke/TIA, % 2.1 2.3 0.746
Major bleeding, % 6.2 8.6 0.326
IABP: intra-aortic balloon pump; TIA: transient ischaemic attack.
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p=0.057). The composite end point of all-cause death/re-
infarction was 42.4% in the overall population, signifi-
cantly higher in the IABP group (OR 1.53, 95% CI 
1.03–2.25, p=0.032). All other secondary end points were 
similar between groups. These results (all-cause mortality 
and the composite end point) were consistent in all speci-
fied subgroups (Figures 2 and 3) with the exception of 
patients with previous MI, who had worst outcome with 
IABP, and patients with mechanical complications, with 
better outcome with IABP use.
Table 3 details the multivariate analysis with the inde-
pendent predictors of all-cause in-hospital mortality and the 
composite end point death/re-infarction. IABP use was 
independently associated with worst in-hospital outcome. 
Age and previous stroke/TIA were also independent predic-
tors of outcome. Smoking had a paradoxical beneficial 
effect in outcome.
Survival analysis at six months showed that the use of 
IABP was not an independent predictor of all-cause mortal-
ity (HR 1.138, 95% CI 0.855–1.515), even after adjustment 
in a multivariate model (HR 1.141, 95% CI 0.836–1.559) 
(Figure 4(a)).
Safety
Safety end points results are shown in Table 2. In the entire 
study group, stroke/TIA rate was 2.2% and major bleeding 
occurred in 6.7% of the patients. No significant differences 
Figure 2. Subgroup analysis for the primary end point (all-cause in-hospital mortality).
OR: odds ratio; CI: confidence interval; GFR: glomerular filtration rate; IABP: intra-aortic balloon pump.
Figure 3. Subgroup analysis for the composite end point (in-hospital all-cause mortality and re-infarction).
OR: odds ratio; CI: confidence interval; GFR: glomerular filtration rate; IABP: intra-aortic balloon pump.
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were detected between the IABP group and the group that 
did not receive IABP with respect to the rates of stroke/TIA 
or major bleeding.
Propensity score-matched models
After propensity score matching, patients’ characteristics 
were similar between both groups (Table 4). In this 
matched cohort, death occurred in 39.8% of patients in 
the group without IABP and 40.8% in the group with 
IABP (OR 1.04, 95% CI 0.63–1.74, p=0.865). For the 
composite outcome of death/re-infarction, it occurred in 
41.0% vs. 46.9% respectively (OR 1.27, 95% CI 0.77–
2.11, p=0.349).
In survival analysis, the outcome was identical between 
patients with and without IABP (Figure 4(b)). Also in a Cox 
proportional hazards model, IABP was not associated with a 
different outcome (adjusted HR 0.996, 95% CI 0.674–1.471).
Discussion
In our large nationwide registry of patients with acute MI, 
the use of IABP was not associated with a reduction in in-
hospital all-cause mortality/re-infarction or six-month all-
cause mortality in the subgroup of patients with cardiogenic 
shock complicating MI for whom early revascularization 
was planned. These results are also consistent in a subgroup 
analysis, with the exception of patients with mechanical 
complications, where IABP was associated with improved 
in-hospital outcome.
Our results were further consolidated by the use of pro-
pensity score matching, which allowed an adequate balance 
of baseline and treatment characteristics. The absence of 
benefit with IABP after propensity score matching analysis 
remained consistent with our short-term estimates.
In previous registries, which represent real-world treat-
ment, the rate of cardiogenic shock in populations with ACS 
ranged from 1% to 4.6%.1,2 Our registry showed a rate of 
4.2%, similar to other registries. Although rare, cardiogenic 
shock is usually a deadly complication of acute myocardial 
infarction. The mortality rate of 40.2% in our study popula-
tion was similar to recent trials, and slightly better than the 
42% to 48% mortality rate reported in older randomized trials 
and registries.1,2,7 Other authors explained this lower rate in 
recent studies with the possible inclusion of a higher percent-
age of patients with mild or moderately severe cardiogenic 
Table 3. Multivariate logistic regression analysis for in-hospital 
all-cause mortality and in hospital death/re-infarction.
 OR 95% CI p-value
In-hospital all-cause death
Age, per 10 years 1.52 1.28–1.80 <0.001
Smoking 0.59 0.36–0.95 0.031
Previous stroke/TIA 2.01 1.11–3.64 0.021
IABP 1.77 1.15–2.73 0.010
In-hospital death/re-infarction
Age, per 10 years 1.49 1.26–1.76 0.040
Smoking 0.62 0.39–0.99 0.046
Previous stroke/TIA 1.81 1.00–3.28 0.049
IABP 2.01 1.31–3.09 0.001
OR: odds ratio; CI; confidence interval; IABP: intra-aortic balloon pump; 
TIA: transient ischaemic attack.
Figure 4. Kaplan–Meier survival analysis comparing patients with and without intra-aortic balloon pump (IABP). (a) Overall study 
population; (b) propensity score matched population.
Timóteo et al. 29
shock. However, our results being similar seems to support 
the fact that they were obtained in a population of patients 
with contemporary treatment and better outcomes. In fact, 
only patients with a planned revascularization were included 
in our study as well as in the IABP-SHOCK 2 trial. If we 
consider all the patients in our registry with cardiogenic 
shock, including patients that were not submitted to early 
invasive strategy, hospital mortality was 49.8%, confirming 
the benefit of early revascularization in these patients.
Previous studies showed that IABP is a potentially valu-
able therapy for circulatory support in cardiogenic shock 
because it ameliorates ischaemia by simultaneously aug-
menting coronary blood flow and reducing myocardial 
oxygen demand.12,13 However, despite the limited evidence 
by randomized controlled trials, IABP is the most com-
monly used mechanical assistance device for patients in 
cardiogenic shock due to acute myocardial infarction. Until 
recently, guidelines from the American Heart Association/
American College of Cardiology and from the European 
Society of Cardiology strongly recommended the use of 
IABP as a class I recommendation for the treatment of 
patients with infarct-related cardiogenic shock.3,4 However, 
that strategy was developed in the era of thrombolytic treat-
ment of acute myocardial infarction. At that time, the 
SHOCK trial showed that thrombolytic therapy, IABP and 
revascularization by PCI/CABG were associated with 
Table 4. Clinical characteristics by study group after propensity score matching.
Without IABP 
n=161
With IABP 
n=98
p-value
Age, years 66 ± 13 66 ± 12 0.979
Male gender, % 65.8 65.3 0.930
BMI, kg/m2 27.1 (24.7–29.7) 26.2 (24.5–28.3) 0.073
Risk factors, %  
 Hypertension 64.0 64.3 0.960
 Hyperlipidaemia 49.7 51.0 0.835
 Diabetes 33.5 34.7 0.849
  Smoking 29.2 28.2 0.644
Previous history, %  
  Myocardial infarction 8.7 9.2 0.893
  PCI 6.8 8.2 0.690
  CABG 0 1.0 0.378
  Stroke/TIA 9.3 13.3 0.321
  PAD 3.1 3.1 1.000
Initial presentation  
  EMS, % 10.6 11.2 0.867
  Heart rate, beats/min 88 ± 28 88 ± 29 0.888
  SBP, mmHg 105 ± 31 104 ± 31 0.791
  Killip class IV, admission, % 42.2 47.4 0.424
  STEMI, % 82.0 76.5 0.414
   Anterior 67.4 69.3 0.777
   Thrombolysis 14.5 9.1 0.287
GRACE risk score 175 (158–203) 193 (154–218) 0.418
Multivessel disease, % 65.2 63.3 0.750
Left main disease, % 19.3 24.5 0.318
Treatment, %  
  ASA 96.3 98.0 0.714
  Clopidogrel 81.4 86.7 0.260
  ACEI 47.6 55.1 0.218
  Beta-blocker 39.1 43.9 0.415
  Statin 72.0 76.5 0.427
  PCI 86.3 86.7 0.927
  CABG 1.2 3.1 0.107
Mechanical complications, % 11.2 11.2 0.991
Stroke /TIA, % 2.5 3.1 1.000
Major bleeding, % 5.6 8.2 0.417
In-hospital death, % 39.8 40.8 0.865
In-hospital re-infarction, % 3.1 8.2 0.083
Death/re-infarction, % 41.0 46.9 0.349
IABP: intra-aortic balloon pump; BMI: body mass index; PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting;  
TIA: transient ischaemic attack; PAD: peripheral arterial disease; SBP: systolic blood pressure; EMS: emergency medical system; STEMI: ST elevation 
myocardial infarction; GRACE: Global Registry of Acute Coronary Events; ASA: acetyl salicylic acid; ACEI: angiotensin converting enzyme inhibitor.
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lower in-hospital mortality rates. A strategy of early throm-
bolysis and IABP was particularly recommended in hospi-
tals without revascularization facilities, followed by 
immediate transfer for coronary angiography.14 This benefit 
was subsequently supported by a 12-month analysis that 
favoured IABP after thrombolytic therapy in cardiogenic 
shock complicating myocardial infarction, particularly 
when early revascularization was not available.15 Also 
patients that underwent emergent revascularization but did 
not receive previous thrombolytic therapy had lower 
12-month mortality with IABP (42% vs. 60%).
The GRACE registry showed that 4.6% of patients with 
ACS developed cardiogenic shock.1,2 From these, 57% 
underwent coronary angiography and only 47% coronary 
revascularization. In our registry, only 43.6% underwent 
early coronary angiography. However, the revasculariza-
tion rate in the group submitted to coronary angiography 
was very high (83.4% had successful PCI and 2.4% CABG). 
In the Euro Heart Survey, only 25% of acute MIs compli-
cated by cardiogenic shock undergoing PCI were treated 
with IABP.16 In our registry, that rate was even lower.
In a more contemporary treatment era, where emergent 
revascularization is the cornerstone treatment to improve 
survival, evidence does not seem to favour IABP use. Both 
the Euro Heart Survey on Percutaneous Coronary 
Intervention data analysis and several meta-analyses showed 
that the use of IABP was not associated with any survival 
improvement.5,16 This subject was addressed in the IABP-
SHOCK 2 trial, which showed no benefit with the use of 
IABP in patients with cardiogenic shock in the contemporary 
era of MI treatment.7 There was no immediate improvement 
in haemodynamic status or in the systemic inflammatory 
response syndrome. Although there was a positive effect of 
IABP on multiorgan dysfunction in the first few days, this 
effect was no longer present at day four. These results were 
further supported at 12-month follow-up, with no benefit of 
IABP in all-cause mortality (HR 1.01 95% CI 0.86–1.18, 
p=0.91) or re-infarction (HR 2.60, 95% CI 0.95–7.10, 
p=0.05).17 However, these results do not reflect real-world 
treatment and the translation to real-life populations is not 
always adequate due to different characteristics of patient 
populations and centres.
We decided to study the role of IABP treatment in a large 
national registry of ACS in patients with acute MI compli-
cated by cardiogenic shock. This registry expresses contem-
porary treatment in real life, and we sought to study the 
potential beneficial or harmful effects of IABP. We showed 
that IABP use was not associated with any improvement in 
outcome in patients with MI-related cardiogenic shock. Only 
in patients with mechanical complications did IABP improve 
survival and reduce the composite end point of death/re-
infarction. Thus, our study is in line with previous trial, 
registries and meta-analyses5–7,18–21 and supports the recent 
downgrading of IABP indication in patients with MI-related 
cardiogenic shock.18,19 In these guidelines, IABP is a class 
IIIA recommendation for routine use in acute MI complicated 
by cardiogenic shock and a class IIaC recommendation in the 
case of cardiogenic shock due to mechanical complications.
Particularly interesting was the finding that patients with 
previous MI had a more unfavourable outcome with IABP 
support compared with those without previous MI. There 
was no evident explanation, except from the longer symp-
tom to admission time (134 min vs. 68 min, p=0.09), lower 
frequency of prior cardiac medication use and previous 
revascularization, and higher frequency of STEMI and left 
main stenosis (Supplementary Material Table 2 online).
The timing of IABP deployment could be important but 
we did not address that subject in our study. However, a 
recent analysis of the Swedish Coronary Angiography and 
Angioplasty Registry (SCCAR) showed that the timing of 
IABP insertion (before or after primary PCI) was not asso-
ciated with a different outcome.22
Limitations
Our study is an observational and non-randomized study. 
Although most Portuguese centres participated in the regis-
try, at different treatment levels, not all were included.
Only patients with quick access to catheterization facili-
ties and who were submitted to urgent coronary angiogra-
phy, with IABP availability, were included in the analysis. 
Coronary revascularization has important implications in 
outcome and we tried to obtain a homogeneous population 
with very specific inclusion criteria.
In our registry, we lack complete information on the 
type and timing of mechanical complications and subse-
quent treatment. Patients with cardiogenic shock and 
mechanical complications had a significantly higher hospi-
tal mortality (55.0% vs. 40.2%, p=0.038). We also found 
that only 20% of the patients with MI and a mechanical 
complication were treated with IABP, with a mortality rate 
of 25.0% compared with 62.5% in the group without IABP 
(p=0.020). A detailed analysis on the type of mechanical 
complication and specific treatment would be important to 
explain the rate of IABP use and the benefits associated 
with its use. There might have been some treatment bias 
from the attending physician when choosing to use IABP. 
This is an interesting subject to study in the future, to under-
stand whether IABP is more used in patients with specific 
types of mechanical complications or in patients submitted 
to medical or surgical treatment. Also in our study, we only 
considered patients with early cardiogenic shock and early 
invasive strategy including IABP in the first 24 h. However, 
some mechanical complications are usually late complica-
tions and later IABP use was not captured in our study. 
Despite this, we believe that most complications occurred 
early and were the cause of cardiogenic shock.
Unexpectedly, we found a similar rate of stroke/TIA and 
bleeding in both study groups. A possible explanation was 
that our registry could not be capable of capturing those 
adverse events. However, the definitions were very objective 
and it does not seem to be the case. If we had considered also 
Timóteo et al. 31
minor bleedings, the results would probably have been worse 
for IABP, but we decided not to use that end point because 
minor bleeding definition is more subjective and it might be 
incorrectly represented in the registry.
Conclusions
In a large population of patients with acute MI complicated 
by cardiogenic shock, IABP was used in less than one-fifth 
of patients submitted to coronary angiography. In this 
nationwide registry, IABP use was associated with a neutral 
effect in outcome. Only patients with mechanical compli-
cations had significant benefits in survival with IABP use.
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